We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1501
MarketAxess Holdings
MKTX
$5.72B
| $195K | ﹤0.01% |
871
+349
| +67% | +$76.7K |
|
1502
Zimmer Biomet
ZBH
$19B
| $194K | ﹤0.01% |
2,132
+1,202
| +129% | +$116K |
|
1503
Monro
MNRO
$383M
| $194K | ﹤0.01% |
12,988
-42,205
| -76% | -$608K |
|
1504
Northwest Bancshares
NWBI
$2.25B
| $191K | ﹤0.01% |
14,971
+11,761
| +366% | +$143K |
|
1505
KeyCorp
KEY
$23.5B
| $186K | ﹤0.01% |
+10,660
| New | +$165K |
|
1506
AnaptysBio
ANAB
$1.7B
| $184K | ﹤0.01% |
8,274
| – | – |
|
|
MZTI
1507
The Marzetti Company
MZTI
$3.07B
| $183K | ﹤0.01% |
1,061
-834
| -44% | -$144K |
|
1508
Ametek
AME
$55.9B
| $182K | ﹤0.01% |
1,005
-12
| -1% | -$2.06K |
|
1509
AbCellera Biologics
ABCL
$4.02B
| $182K | ﹤0.01% |
53,000
-894,751
| -94% | -$2.23M |
|
1510
First Citizens BancShares
FCNCA
$24.4B
| $180K | ﹤0.01% |
92
+28
| +44% | +$50.8K |
|
1511
IPG Photonics
IPGP
$3.29B
| $177K | ﹤0.01% |
2,583
-2,115
| -45% | -$132K |
|
1512
Corning
GLW
$132B
| $176K | ﹤0.01% |
3,354
-34
| -1% | -$1.59K |
|
1513
Clearway Energy Class C
CWEN
$6.65B
| $176K | ﹤0.01% |
5,489
-430
| -7% | -$12.8K |
|
1514
Columbia Sportswear
COLM
$2.91B
| $175K | ﹤0.01% |
2,862
-2,379
| -45% | -$153K |
|
|
CHA
1515
Chagee Holdings Ltd
CHA
$1.97B
| $172K | ﹤0.01% |
+6,600
| New | +$202K |
|
1516
Expeditors International
EXPD
$24.8B
| $171K | ﹤0.01% |
1,500
-10,785
| -88% | -$1.21M |
|
1517
Charter Communications
CHTR
$17.7B
| $170K | ﹤0.01% |
415
+282
| +212% | +$108K |
|
1518
Franklin Templeton
BEN
$17.7B
| $169K | ﹤0.01% |
+7,098
| New | +$146K |
|
1519
Baker Hughes
BKR
$61.7B
| $166K | ﹤0.01% |
4,330
-88
| -2% | -$3.32K |
|
1520
NB Bancorp
NBBK
$980M
| $165K | ﹤0.01% |
9,224
-487
| -5% | -$8.22K |
|
1521
ResMed
RMD
$34B
| $165K | ﹤0.01% |
638
-7
| -1% | -$1.67K |
|
1522
NuScale Power
SMR
$4B
| $163K | ﹤0.01% |
4,111
+3,186
| +344% | +$79.9K |
|
|
JNPR
1523
DELISTED
Juniper Networks
JNPR
| $162K | ﹤0.01% |
4,046
-218
| -5% | -$7.81K |
|
1524
Rayonier
RYN
$6.14B
| $161K | ﹤0.01% |
7,597
-1,488
| -16% | -$34K |
|
1525
Air Products & Chemicals
APD
$68B
| $160K | ﹤0.01% |
569
-49
| -8% | -$13.4K |
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.